Intelligence / B2B SaaS / Acquisitions / Sangamo Therapeutics, INC
Sangamo Therapeutics, INC
21 Sept 2026: Sold assets or a business (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.
- Filed
- 21 Sept 2026
- Ticker
- SGMOQ
- Role
- Sold assets or a business
- Sector
- Pharma and biotech
- Sic
- 2836
- Items
- 1.03, 2.01, 9.01
- Summary
- below is incorporated into this
- Location
- Richmond, CA
- State
- California
- Country
- United States
- SEC CIK
- 1001233
- Reference
- 0001193125-26-396644
Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.
- Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
- 103 added in the 30 days to 19 Nov 2026.
Find the decision makers at Sangamo Therapeutics, INC
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.
Across AOS Research
Other records for Sangamo Therapeutics, INC in our registers.
More in Sold assets or a business
Acquisitions
Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.